- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-K Annual report
- 10.25 Form of Option Agreement
- 10.28 Development Agreement
- 10.29 Master Services Agreement
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification Pursuant to Rule 13A-14(A) of Joseph K. Belanoff, M.D
- 31.2 Certification Pursuant to Rule 13A-14(A) of Caroline M. Loewy
- 32.1 Certification Pursuant to 18 U.s.c. Section 1350 of Joseph K. Belanoff, M.D.
- 32.2 Certification Pursuant to 18 U.s.c. Section 1350 of Caroline M. Loewy
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-8 No. 333-116127) pertaining to the 2000 Stock Option Plan and the 2004 Equity Incentive Plan of Corcept Therapeutics Incorporated,
(2) Registration Statements (Form S-8 Nos. 333-150199, 333-158406 and 333-164531) pertaining to the 2004 Equity Incentive Plan of Corcept Therapeutics Incorporated, and
(3) Registration Statements (Form S-3 Nos. 333-149087, 333-150204, 333-163140, 333-167211, 333-168928, 333-141881, 333-150232 and 333-150259) of Corcept Therapeutics Incorporated and in the related Prospectuses;
of our reports dated March 15, 2011, with respect to the financial statements of Corcept Therapeutics Incorporated (a development stage company) and the effectiveness of internal control over financial reporting of Corcept Therapeutics Incorporated included in this Annual Report (Form 10-K) of Corcept Therapeutics Incorporated for the year ended December 31, 2010.
/s/ Ernst & Young LLP
Palo Alto, California
March 15, 2011